Naoya Oribe, Yoji Hirano, Shigenobu Kanba1, Elisabetta Del Re2, Larry Seidman3, Raquelle Mesholam-Gately3, Jill M Goldstein4, Martha Shenton5, Kevin M Spencer6, Robert W McCarley2, Margaret Niznikiewicz7. 1. Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; 2. Clinical Neuroscience Division, Laboratory of Neuroscience, VA Boston Healthcare System-Brockton Division, Department of Psychiatry, Harvard Medical School, Brockton, MA; 3. Massachusetts Mental Health Center Public Psychiatry Division, Beth Israel Deaconess Medical Center, Department of Psychiatry, Harvard Medical School, Boston, MA; 4. Departments of Psychiatry and Medicine, Harvard Medical School, Brigham and Women's Hospital, Connors Center for Women's Health and Gender Biology, Boston, MA; 5. Psychiatry Neuroimaging Laboratory, Departments of Psychiatry and Radiology, Brigham and Women's Hospital, Boston, MA; Research and Development, Boston Veterans Affairs Healthcare System, Boston Division, Harvard Medical School, Boston, MA. 6. Neural Dynamics Laboratory, Department of Psychiatry, Boston Veterans Affairs Healthcare System, Boston Division, Harvard Medical School, Boston, MA; 7. Clinical Neuroscience Division, Laboratory of Neuroscience, VA Boston Healthcare System-Brockton Division, Department of Psychiatry, Harvard Medical School, Brockton, MA; Margaret_Niznikiewicz@hms.harvard.edu.
Abstract
OBJECTIVE: To understand the underlying dynamic neurophysiological changes over the course of schizophrenia, it is important to study subjects longitudinally from the early stage of the illness. We previously reported that visual P300 was already impaired in patients with first-episode schizophrenia (FESZ). This study demonstrates how the visual P300, as well as earlier components P1, N1, and N200, changed at the 1-year follow-up after their initial measurement. METHODS: Visual ERPs were recorded with the same experimental paradigm and acquisition protocol at both time points in FESZ (n = 18) and healthy comparison subjects (n = 24). Participants silently counted infrequent target stimuli ("x") amid standard stimuli ("y") presented on the screen while the 64-channel electroencephalogram was recorded. RESULTS: FESZ showed smaller visual P300, N200, P1 (trend level) amplitude and delayed P300 and N1 latency at both time points; however, only P300 showed progressive amplitude reduction over the course of the illness at 1-year follow-up. P300 latency did not change over time in either group. FESZ showed significantly reduced Spatial Span total score at both time points, and there was a significant negative correlation between P300 peak amplitude and the Brief Psychiatric Rating Scale positive symptom score at baseline. CONCLUSION: These data show progressive P300 amplitude reduction in response to visual stimuli in the early stage of schizophrenia. These visual P300 findings support the concept of progression of schizophrenia, suggesting the usefulness of the visual P300 as a biological marker of progression.
OBJECTIVE: To understand the underlying dynamic neurophysiological changes over the course of schizophrenia, it is important to study subjects longitudinally from the early stage of the illness. We previously reported that visual P300 was already impaired in patients with first-episode schizophrenia (FESZ). This study demonstrates how the visual P300, as well as earlier components P1, N1, and N200, changed at the 1-year follow-up after their initial measurement. METHODS: Visual ERPs were recorded with the same experimental paradigm and acquisition protocol at both time points in FESZ (n = 18) and healthy comparison subjects (n = 24). Participants silently counted infrequent target stimuli ("x") amid standard stimuli ("y") presented on the screen while the 64-channel electroencephalogram was recorded. RESULTS: FESZ showed smaller visual P300, N200, P1 (trend level) amplitude and delayed P300 and N1 latency at both time points; however, only P300 showed progressive amplitude reduction over the course of the illness at 1-year follow-up. P300 latency did not change over time in either group. FESZ showed significantly reduced Spatial Span total score at both time points, and there was a significant negative correlation between P300 peak amplitude and the Brief Psychiatric Rating Scale positive symptom score at baseline. CONCLUSION: These data show progressive P300 amplitude reduction in response to visual stimuli in the early stage of schizophrenia. These visual P300 findings support the concept of progression of schizophrenia, suggesting the usefulness of the visual P300 as a biological marker of progression.
Authors: Joseph I Friedman; Cheuk Tang; David Carpenter; Monte Buchsbaum; James Schmeidler; Lauren Flanagan; Shana Golembo; Isabella Kanellopoulou; Johnny Ng; Patrick R Hof; Philip D Harvey; Nicholas D Tsopelas; Daniel Stewart; Kenneth L Davis Journal: Am J Psychiatry Date: 2008-06-16 Impact factor: 18.112
Authors: Franc C L Donkers; Shane R Schwikert; Anna M Evans; Katherine M Cleary; Diana O Perkins; Aysenil Belger Journal: Front Psychiatry Date: 2011-08-22 Impact factor: 4.157
Authors: Vibeke S Catts; Samantha J Fung; Leonora E Long; Dipesh Joshi; Ans Vercammen; Katherine M Allen; Stu G Fillman; Debora A Rothmond; Duncan Sinclair; Yash Tiwari; Shan-Yuan Tsai; Thomas W Weickert; Cynthia Shannon Weickert Journal: Front Cell Neurosci Date: 2013-05-15 Impact factor: 5.505
Authors: Claudia Lainscsek; Aaron L Sampson; Robert Kim; Michael L Thomas; Karen Man; Xenia Lainscsek; Neal R Swerdlow; David L Braff; Terrence J Sejnowski; Gregory A Light Journal: Proc Natl Acad Sci U S A Date: 2019-02-11 Impact factor: 11.205
Authors: Holly K Hamilton; Scott W Woods; Brian J Roach; Katiah Llerena; Thomas H McGlashan; Vinod H Srihari; Judith M Ford; Daniel H Mathalon Journal: Schizophr Bull Date: 2019-09-11 Impact factor: 9.306
Authors: Amy Trongnetrpunya; Paul Rapp; Chao Wang; David Darmon; Michelle E Costanzo; Dominic E Nathan; Michael J Roy; Christopher J Cellucci; David Keyser Journal: Front Hum Neurosci Date: 2019-10-25 Impact factor: 3.169
Authors: Giulia M Giordano; Luigi Giuliani; Andrea Perrottelli; Paola Bucci; Giorgio Di Lorenzo; Alberto Siracusano; Francesco Brando; Pasquale Pezzella; Michele Fabrazzo; Mario Altamura; Antonello Bellomo; Giammarco Cascino; Anna Comparelli; Palmiero Monteleone; Maurizio Pompili; Silvana Galderisi; Mario Maj Journal: J Clin Med Date: 2021-12-13 Impact factor: 4.241